Inovio Pharmaceuticals (Nasdaq: INO) reported recent preclinical data summaries for their COVID-19 DNA vaccine called INO-4800 demonstrating promising information. Namely, the sponsor’s tests demonstrated robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2. The study was published in a peer-reviewed journal Nature Communications and titled “Immunogenicity of a DNA vaccine candidate for COVID-19.” The preclinical study was authored by scientists and collaborators from The Wistar Institute, the University of Texas, Public Health England, Fudan University and Advaccine.
TrialSite News provides a breakdown of this recent announcement. But first a brief background.
Inovio has made significant progress with their COVID-19 vaccine development due to their DNA medicine platform’s suitability for vaccine development targeting emerging viruses with pandemic potential. Inovio claimed in their recent press release that they were the first to advance its DNA vaccine (INO-4700) against MERS-CoV, a related coronavirus from the Middle East, into evaluation in humans in collaboration with GeneOne Life Science and the Walter Reed Army Institute of Research....
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).